Quality of Life under Capecitabine (Xeloda®) in Patients with Metastatic Breast Cancer: Data from a German Non-Interventional Surveillance Study. 6. Juni 2014 Müller, V., Fuxius, S., Steffens, C.-C., Lerchenmüller, C., Luhn, B., Vehling-Kaiser, U., Hurst, U., Hahn, L.-J., Soeling, U., Wohlfarth, T., Zaiss, M., 2014. Oncol Res Treat 37, 6–6. doi:10.1159/000369487 Abstract Final efficacy and safety analysis of the CARIN phase III trial: Cap and Bev with or without Vin in 1st line metastatic breast cancer (MBC). Welt, A., Marschner, N., Lerchenmüller, C., Decker, T., Salat, C., Busies, S., Hegewisch-Becker, S., 2014. Ann Oncol, ESMO (Madrid) 25, iv119 (359PD). doi:10.1093/annonc/mdu329.9… Weiterlesen Abstract P5-19-11: Noninterventional study HELENA – Advanced (metastatic or locally recurrent, inoperable) HER2-positive breast cancer: First-Line trEatmeNt with pertuzumAb after adjuvant trastuzumab therapy. Thill, M., Ziegler-Löhr, K., Wagner, H., Helling-Giese, G., Greinemann, J., Schmalhofer, O., Reichert, D., 2015. Cancer Res 75 (9 Suppl)(P5-19–11). doi:10.1158/1538-7445.SABCS14-P5-19-11… Weiterlesen